logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

The pharmaceutical industry reaches a record figure for research and development of new medicines

2021 closes with the best R&D investment figures ever: the pharmaceutical industry allocates 1,267 million euros to both private and public projects.

La industria farmacéutica alcanza una cifra récord en inversión y desarrollo de nuevos medicamentos

Source: elespanol.com

Investing in the research and development of new medicines is an essential activity for guaranteeing health and social well-being and improving the healthcare system. A country that is committed to biomedical research enables, among other things, rapid access to medicines or the development of drugs for diseases for which there is as yet no treatment.

Aware of the importance of allocating more money to the development of new drugs, the pharmaceutical industry invested 1,267 million euros in R&D in 2021, a historic figure that represents 9.2% more than in 2020, the second highest investment figure despite the difficulties caused by the pandemic. This is reflected in the data obtained by the Survey on R&D Activities developed by Farmaindustria, the National Business Association of the Pharmaceutical Industry established in Spain.

“The sector’s constant commitment to investment in R&D is reflected in the fact that almost 20% of all industrial R&D carried out in Spain is carried out by the pharmaceutical industry. This represents more than 9% of the R&D carried out by the entire business sector in our country, and 6.1% of the total research of the Spanish economy, taking into account public and private research”, emphasises Farmaindustria’s general director, Juan Yermo.

Of this R&D investment, 674 million euros went to the companies’ own research centres (intramural R&D), which corresponds to 53% of total expenditure. The remaining 593 million euros went to research contracts with hospitals, universities and public and private centres (extramural R&D), an example of public-private collaboration. Moreover, all of Spain’s autonomous communities benefited from this investment, although the Community of Madrid (34%) and Catalonia (31%) invested the most.

More than 60% of the investment, earmarked for clinical trials

The survey conducted by Farmaindustria also shows that more than 60% (789 million euros) of the figure invested in R&D during 2021 was earmarked for clinical trials, which are key to developing cutting-edge treatments and offering new hope to patients. Indeed, since 2011, investment in clinical research has increased by an annual average of 5.3%, from €470 million to €789 million in 2021.

Of the money invested in clinical research, 35% (275 million euros) went to phase I and II trials, the earliest stages of drug research and development, which are designed to test experimental treatments in people with a given disease. These two are the most complicated from a scientific point of view because experts need to give a safe treatment and observe its reaction in the body.

In addition to investing in clinical trials, the pharmaceutical industry also invested a total of 403 million euros in the field of biotechnology, 31.8% of total R&D investment in 2021. This decision is based on the important role of biotechnology in drug development. Thirty-three percent of innovative pharmaceutical companies use biotechnology or tools of biotechnological origin in the pre-clinical phase, intended for trials and tests to learn about the activity of the drug, and 57% also use them in the next phase, the clinical phase, which is already carried out on humans.

Higher quality for the entire healthcare system

This investment in R&D by the pharmaceutical industry during the 2021 financial year has not only had a significant impact on drug development, but has also strengthened employment in R&D departments, which is characterised by its high level of skills and equality. Thus, direct employment in the pharmaceutical industry in this area grew by 6.5% in 2021, reaching 5,393 people, the highest figure ever recorded in the sector.

Moreover, in terms of gender issues, currently two thirds of R&D employees in this sector are women and one in four female researchers in the Spanish industrial sector come from pharmaceutical companies, as shown by the latest data collected by the INE. “Quality employment is synonymous with wealth for countries. If we add that employment in innovative pharmaceutical companies is, for the most part, permanent and equal, we have the ideal equation to consider the pharmaceutical industry as a strategic sector for Spain,” concludes Yermo.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.